Physician profile
Jorge Osorio
NPI 1104810936
$17,271.97
in general payments reported to CMS, 2019-2025
31 companies · $2,083 in 2025
The $2,083 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,415 · 2020: $2,909 · 2021: $3,667 · 2022: $1,706 · 2023: $2,321 · 2024: $2,171 · 2025: $2,083.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,338 · Education: $237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,337.64 |
| Education | $237.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,973.86 | 2019-2025 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $2,613.78 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $1,839.44 | 2019-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $1,822.42 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,575.47 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $1,138.13 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Mannkind Corporation | $1,027.03 | 2019-2025 | Afrezza |
| Kowa Pharmaceuticals America, INC. | $459.76 | 2019-2025 | Zoryve |
| Amarin Pharma, INC. | $446.41 | 2019-2022 | |
| Allergan, INC. | $438.61 | 2019-2020 | |
| Abbvie INC. | $410.80 | 2020-2024 | |
| Sanofi-Aventis U.S. LLC | $386.36 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $297.34 | 2021 | |
| Merck Sharp & Dohme LLC | $284.54 | 2019-2022 | |
| Exact Sciences Corporation | $280.28 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $212.64 | 2019-2024 | |
| Astellas Pharma US INC | $198.15 | 2019-2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $194.87 | 2019-2025 | |
| Abiomed | $156.45 | 2025 | |
| Janssen Pharmaceuticals, INC | $119.91 | 2020-2021 | |
| Abbott Laboratories | $88.21 | 2024 | Architect |
| Horizon Therapeutics Plc | $77.96 | 2019-2023 | Krystexxa |
| Qiagen, LLC | $69.46 | 2019 | |
| Hikma Pharmaceuticals USA | $41.43 | 2021-2022 | |
| Esperion Therapeutics, INC. | $26.55 | 2020 | |
| Shield Therapeutics INC | $19.94 | 2023 | Accrufer |
| Bayer Healthcare Pharmaceuticals INC. | $16.24 | 2024 | |
| Avanir Pharmaceuticals, INC. | $14.99 | 2021 | |
| Currax Pharmaceuticals LLC | $13.83 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.69 | 2020 | |
| Eyevance Pharmaceuticals LLC | $13.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Osorio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.